Circulating levels and prognostic cut‐offs of sST2, hs‐cTnT, and NT‐proBNP in women vs. men with chronic heart failure

To define plasma concentrations, determinants, and optimal prognostic cut‐offs of soluble suppression of tumorigenesis‐2 (sST2), high‐sensitivity cardiac troponin T (hs‐cTnT), and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) in women and men with chronic heart failure (HF).

[1]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[2]  C. Scott,et al.  Sex-specific cut-off values for soluble suppression of tumorigenicity 2 (ST2) biomarker increase its cardiovascular prognostic value in the community , 2021, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[3]  R. Doughty,et al.  NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories. , 2021, JACC. Heart failure.

[4]  M. Emdin,et al.  Epidemiological and clinical boundaries of heart failure with preserved ejection fraction. , 2021, European journal of preventive cardiology.

[5]  P. Ponikowski,et al.  Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. , 2021, Journal of cardiac failure.

[6]  B. Ploeger,et al.  NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure , 2021, Clinical pharmacology and therapeutics.

[7]  P. Ponikowski,et al.  Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure , 2021, European journal of heart failure.

[8]  M. Domingo,et al.  Gender-Related Differences in Heart Failure Biomarkers , 2021, Frontiers in Cardiovascular Medicine.

[9]  J. Januzzi,et al.  Heart Failure With Reduced Ejection Fraction: A Review. , 2020, JAMA.

[10]  M. Emdin,et al.  Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction. , 2020, European journal of preventive cardiology.

[11]  Jiandie D. Lin,et al.  The obesity-induced adipokine sST2 exacerbates adipose Treg and ILC2 depletion and promotes insulin resistance , 2020, Science Advances.

[12]  R. D. de Boer,et al.  Sex‐related differences in contemporary biomarkers for heart failure: a review , 2020, European journal of heart failure.

[13]  K. Sliwa,et al.  Sex differences in heart failure. , 2019, European heart journal.

[14]  G. Filippatos,et al.  Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations , 2019, European journal of heart failure.

[15]  Thomas J. Wang,et al.  Effect of Testosterone on Natriuretic Peptide Levels. , 2019, Journal of the American College of Cardiology.

[16]  H. Brunner-La Rocca,et al.  Natriuretic Peptides in Chronic Heart Failure , 2018, Cardiac failure review.

[17]  Akshay S. Desai,et al.  Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. , 2019, Journal of the American College of Cardiology.

[18]  U. Eriksson,et al.  Mechanisms of sex differences in atrial fibrillation: role of hormones and differences in electrophysiology, structure, function, and remodelling. , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[19]  P. Voisine,et al.  Transcatheter Mitral-Valve Repair in Patients with Heart Failure. , 2019, The New England journal of medicine.

[20]  M. Emdin,et al.  sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. , 2018, Journal of the American College of Cardiology.

[21]  B. Schroen,et al.  Sex‐specific associations of obesity and N‐terminal pro‐B‐type natriuretic peptide levels in the general population , 2018, European journal of heart failure.

[22]  J. Mascherbauer,et al.  Gender-related differences in heart failure with preserved ejection fraction , 2018, Scientific Reports.

[23]  L. Tavazzi,et al.  Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis , 2018, Circulation.

[24]  M. Pfisterer,et al.  Heart failure with mid‐range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME‐CHF) , 2017, European journal of heart failure.

[25]  B. Lindahl,et al.  Impact of Sex on Cardiac Troponin Concentrations-A Critical Appraisal. , 2017, Clinical chemistry.

[26]  H. D. den Ruijter,et al.  The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction , 2017, European journal of heart failure.

[27]  J. Butler,et al.  Heart failure with reduced ejection fraction , 2017, Nature Reviews Disease Primers.

[28]  M. Emdin,et al.  Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis. , 2017, JACC. Heart failure.

[29]  A. Mebazaa,et al.  Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. , 2017, JACC. Heart failure.

[30]  M. de Antonio,et al.  Impact of diabetes on the predictive value of heart failure biomarkers , 2016, Cardiovascular Diabetology.

[31]  M. Şeneş,et al.  Relationship between high sensitivity troponins and estimated glomerular filtration rate. , 2016, Clinical biochemistry.

[32]  A. Jaffe,et al.  Soluble ST2 and galectin-3 in pediatric patients without heart failure. , 2015, Clinical biochemistry.

[33]  M. Pfisterer,et al.  Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction , 2015, European journal of heart failure.

[34]  A. Jaffe,et al.  Soluble ST2--analytical considerations. , 2015, The American journal of cardiology.

[35]  S. Hazen,et al.  Prognostic comparison of different sensitivity cardiac troponin assays in stable heart failure. , 2015, The American journal of medicine.

[36]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[37]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[38]  M. Hochadel,et al.  Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the Heart Failure Survival Score , 2015, Clinical Research in Cardiology.

[39]  J. Cohn,et al.  Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial , 2014, Circulation. Heart failure.

[40]  Thomas J. Wang,et al.  Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. , 2014, JACC. Heart failure.

[41]  J. McMurray,et al.  Prognostic Effect of High-Sensitive Troponin T Assessment in Elderly Patients With Chronic Heart Failure: Results From the CORONA Trial , 2013, Circulation. Heart failure.

[42]  R. D. de Boer,et al.  Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial). , 2013, American heart journal.

[43]  V. Cameron,et al.  The Singapore Heart Failure Outcomes and Phenotypes (SHOP) study and Prospective Evaluation of Outcome in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (PEOPLE) study: rationale and design. , 2013, Journal of cardiac failure.

[44]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[45]  R. Vasan,et al.  Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. , 2012, Clinical chemistry.

[46]  L. Tavazzi,et al.  Serial Measurement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients With Chronic Heart Failure: Data From 2 Large Randomized Clinical Trials , 2012, Circulation.

[47]  L. Stevens,et al.  Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  C. Pike,et al.  Androgens regulate neprilysin expression: role in reducing β‐amyloid levels , 2008, Journal of neurochemistry.

[49]  A. Clerico,et al.  Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. , 2001, Clinical science.

[50]  M. L. Kuroski de Bold.  Estrogen, natriuretic peptides and the renin-angiotensin system. , 1999, Cardiovascular research.